5th Novel Conjugates Summit

Novel conjugates have become one of the most competitive and rapidly evolving areas in the precision oncology landscape. Companies are looking beyond traditional ADCs towards novel mechanism of action payloads and differentiated targeting formats for overcoming drug resistance, improved therapeutic windows and to make an impact in cancers which don’t respond to traditional ADCs, as well as the exploration of non-oncology indications.

The 5th Novel Conjugates Summit is the industry’s only dedicated meeting for an insider view into which novel approaches are currently being explored, what benefit each approach has and the directions the space is heading.

Attendees gain valuable competitive insight into emerging technologies, early data, and the rationale behind each approach, from established pharma leaders to the newest biotech entrants. Whether your goal is to benchmark your pipeline, explore partnership opportunities, or stay ahead of fast-moving design trends, this summit offers a front-row seat to the next wave of conjugate innovation.


URLs:
Website: https://go.evvnt.com/3359045-0?pid=2874
Brochure: https://go.evvnt.com/3359045-3?pid=2874

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Prices:
Drug Developer Pricing - 3 Day Pass (Workshop Day + Conference): USD 4397.00,
Drug Developer Pricing - 2 Day Pass (Conference Only): USD 3099.00,
Academic Pricing - 3 Day Pass (Workshop Day + Conference): USD 3797.00,
Academic Pricing - 2 Day Pass (Conference Only): USD 2699.00,
Solutions Provider Pricing - 3 Day Pass (Workshop Day + Conference): USD 5297.00,
Solutions Provider Pricing - 2 Day Pass (Conference Only): USD 3799.00

Speakers: Wei He, Chief Scientific Officer, Accutar Biotechnology, Mahendra Deonarain, Chief Executive Officer, Antikor, Sujiet Puthenveetil, Director - Antibody Drug Conjugates and Radioconjugates, AstraZeneca, Alice Chen, Chief Scientific Officer, Baylink Bioscience, Yu-Shin Hsu, Research Analyst Lead, Beacon, Tiffany Thorn, Chief Executive Officer, BiVictriX Therapeutics, Michael Alonso, Scientific Co-founder and SVP Research, Bolt Biotherapeutics, Nick Yoder, Executive Director, Dyne Therapeutics, Joe Nabhan, Chief Scientific Officer, K2B Therapeutics Inc., Andrea Geist, Senior Scientist, PROxAb Shuttle, Merck, Lan Xu, Drug Discovery and Translational Medicine Advisor, Polymed Biopharmaceuticals, Dan Shores, Patent Attorney, Rothwell Figg, Lucas Bethge, Vice President and Group Lead - Oligonucleotide Chemistry, Silence Therapeutics, Garrett Gross, Director, Research Innovation and Protein Engineering, Sutro Biopharma, Dori Thomas-Karyat, Founder and Chief Executive Officer, Synthis Therapeutics, Inc, Caitlyn Miller, CEO and Co-Founder, TwoStep Therapeutics, Arne Scheu, Co-Founder and Chief Executive Officer, Valink Therapeutics, Irsyad Khairil, Co-Founder and Chief Technology Officer, Valink Therapeutics, Hong Xin, Senior Director - New Venture, Search and Evaluation, Johnson and Johnson, Vikas Goyal, Partner, Growth Investments, Longwood Funds, Carla Bauer, Director, Search and Evaluation, Business Development and Licensing, Merck, Xiaodong Zhang, Director of Search and Evaluation, Oncology and Haematology, Novartis, Juanjo Cragnolini, Associate Director, Search and Evaluation, Oncology R and D, Takeda Pharmaceutical, Philip Low, Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry Purdue University, Purdue University